Portugal – Antineoplastic and immunomodulating agents – 2023/0491 - CANACINUMAB [150 MG/ML; SOL INJ; FRS]
Tender Description
CANACINUMAB [150 MG/ML; SOL INJ; FRS]
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.
